Trial will evaluate the safety and effectiveness of AtriCure’s cryoICE® Ablation System for the treatment of persistent and long-standing persistent atrial fibrillation in open concomitant cardiac surgery MASON, Ohio--(BUSINESS WIRE)--Feb. 5, 2019-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatment for atrial fibrillation (Afib) and left atrial appendage management, today announced the first patient was treated in the ICE-AFIB™ trial (NCT03732794). Following Investigational Device Exemption (IDE) approval by the FDA, the first patient was treated by Dr. Niv Ad, at Washington Adventist Hospital in Takoma...

MASON, Ohio--(BUSINESS WIRE)--Jan. 7, 2019-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced preliminary financial results for the fourth quarter and full year 2018 and provided 2019 financial guidance. Preliminary, unaudited revenue for fourth quarter 2018 is expected to be approximately $52.9 million, reflecting growth of approximately 15% over the fourth quarter of 2017. Based on this preliminary estimate, revenue from U.S. customers is expected to be $43.1 million, reflecting growth of 19% and driven again by st...

MASON, Ohio--(BUSINESS WIRE)--Nov. 8, 2018-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that it will present at the Piper Jaffray 30th Annual Healthcare Conference in New York City on Wednesday, November 28. Management is scheduled to present at 8:00 a.m. Eastern Time. A live audio webcast of the presentation may be accessed by visiting the Investors page of AtriCure’s corporate website at ir.atricure.com. A replay of the presentation will be available for 90 days following the presentation. ...

MASON, Ohio--(BUSINESS WIRE)--Oct. 22, 2018-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that it will be participating in upcoming investor conferences. AtriCure is scheduled to present at the Stifel 2018 Healthcare Conference in New York City on Wednesday, November 14, 2018. Management is scheduled to present at 1:15 p.m. Eastern Time. A live audio webcast of the presentation may be accessed by visiting the Investors page of AtriCure’s corporate website at ir.atricure.com. A replay of th...

MASON, Ohio--(BUSINESS WIRE)--Oct. 4, 2018-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced the pricing of its underwritten offering of 2.5 million shares of its common stock at a price to the public of $30.75 per share pursuant to its existing shelf registration statement. Net proceeds to AtriCure from the offering are expected to be approximately $72 million, after deducting underwriting discounts and commissions and estimated offering expenses. AtriCure has granted to the underwriters of the offering a 30-day option to ...

MASON, Ohio--(BUSINESS WIRE)--Oct. 3, 2018-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced it has commenced an underwritten public offering of 2.5 million shares of its common stock pursuant to its existing shelf registration statement. In connection with this offering, AtriCure plans to grant the underwriters of the offering a 30-day option to purchase up to 375,000 additional shares of common stock at the public offering price less the underwriting discount. AtriCure intends to use the net proceeds from the offering for...

MASON, Ohio--(BUSINESS WIRE)--Aug. 21, 2018-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that it will present at the Morgan Stanley Global Healthcare Conference at the Grand Hyatt Hotel in New York on Friday, September 14, 2018. Management is scheduled to present at 1:00 p.m. Eastern Time. A live audio webcast of the presentation may be accessed by visiting the Investors page of AtriCure’s corporate website at ir.atricure.com. A replay of the presentation will be available for 90 days following the presen...

MASON, Ohio--(BUSINESS WIRE)--Jul. 16, 2018-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that it will present at the Canaccord Genuity 38th Annual Growth Conference at the Intercontinental Hotel in Boston on Thursday, August 9, 2018. Management is scheduled to present at 12:00 p.m. Eastern Time. A live audio webcast of the presentation may be accessed by visiting the Investors page of AtriCure’s corporate website at ir.atricure.com. A replay of the presentation will be available for 90 days follo...

MASON, Ohio--(BUSINESS WIRE)--Jun. 12, 2018-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, will host an analyst and institutional investor meeting on Tuesday, June 26, 2018, in New York City from 8:30 a.m. to approximately 10:00 a.m. Eastern Time. The meeting will focus on clinician guest speakers to provide expert perspectives on broad trends in cardiac surgery and electrophysiology, key clinical trials, and the collaboration between physicians to best treat Afib. Featured speakers: Marc G...

MASON, Ohio--(BUSINESS WIRE)--Apr. 5, 2018-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that it will release its first quarter 2018 financial results on Thursday, April 26, 2018. AtriCure will host a conference call at 4:30 p.m. Eastern Time on Thursday, April 26, 2018 to discuss its first quarter 2018 financial results. The call may be accessed through an operator by calling (844) 884-9951 for domestic callers and (661) 378-9661 for international callers using conference ID number 1288126. A live...

2017 worldwide revenue of $174.7 million – an increase of 12.6% year over year 2017 U.S. revenue of $138.4 million – an increase of 13.1% year over year 2017 international revenue of $36.3 million – an increase of 11.0% year over year MASON, Ohio--(BUSINESS WIRE)--Feb. 26, 2018-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced fourth quarter and full year 2017 financial results. “We realized several accomplishments in 2017 underpinned by our ...

Richard Johnston and Elizabeth D. Krell, Ph.D. are Retiring from the Board of Directors in May MASON, Ohio--(BUSINESS WIRE)--Feb. 20, 2018-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage management, today announced that Scott Drake has been named Board Chairman, effective at the annual meeting in May of this year. Concurrent with this appointment, Richard Johnston, the company’s current chairman, and Elizabeth D. Krell, Ph.D. are planning to retire from the Board of Directors and are not standing for re-election. ...

MASON, Ohio--(BUSINESS WIRE)--Jan. 8, 2018-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced preliminary financial results for the fourth quarter and full year 2017 and provided 2018 financial guidance. Preliminary and unaudited revenue for fourth quarter 2017 is expected to be approximately $46.1 million, reflecting growth of approximately 12% over the fourth quarter of 2016. Based on this preliminary estimate, revenue from U.S. customers is expected to be $36.2 million, reflecting growth of 11% and r...

MASON, Ohio--(BUSINESS WIRE)--Nov. 9, 2017-- AtriCure, Inc. (Nasdaq:ATRC), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that it will present at the Piper Jaffray 29th Annual Healthcare Conference at the Palace Hotel in New York on Tuesday, November 28, 2017. Management is scheduled to present at 9:30 a.m. Eastern Time. A live audio webcast of the presentation may be accessed by visiting the Investors page of AtriCure’s corporate website at ir.atricure.com. A replay of the presentation will be available for 90 days following the ...

MASON, Ohio--(BUSINESS WIRE)--Oct. 20, 2017-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that it will present at the Stifel Healthcare Conference at the Palace Hotel in New York on Tuesday, November 14, 2017. Management is scheduled to present at 4:15 p.m. Eastern Time. A live audio webcast of the presentation may be accessed by visiting the Investors page of AtriCure’s corporate website at ir.atricure.com. A replay of the presentation will be available for 90 days following the presentation. ...

Open-ended AtriClip design, along with smaller profile, allows for greater flexibility in minimally-invasive therapies MASON, Ohio--(BUSINESS WIRE)--Sep. 12, 2017-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage management, today announced that it has launched the AtriClip PRO•V™ Left Atrial Appendage (LAA) Exclusion System in the United States. The new device offers an open-ended design combined with a tip-first closure mechanism to enable easier navigation and placement when operating in minimally-invasive surgery (MIS) environments. Th...

Worldwide revenue of $45.2 million – an increase of 14.0% year over year U.S. revenue of $35.5 million – an increase of 15.1% year over year International revenue of $9.7 million – an increase of 10.2% year over year MASON, Ohio--(BUSINESS WIRE)--Jul. 27, 2017-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced second quarter 2017 financial results. “We are executing on our strategy to deliver solid, balanced, results across our business...

MASON, Ohio--(BUSINESS WIRE)--Jul. 18, 2017-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage management, today announced it has hired Salvatore (Sam) Privitera as its Chief Technology Officer. Mr. Privitera will have responsibility for Research and Development activities, as well as Operations, including manufacturing, supply chain, and quality systems. Most recently, Mr. Privitera served as Vice President of Research and Development at Bard Medical (“BMD”), a division of C.R. Bard (NYSE: BCR), where he helped grow BMD approximately 40% in...

MASON, Ohio--(BUSINESS WIRE)--May 18, 2017-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that it will present at the JMP Securities Life Science Conference at the St. Regis Hotel in New York City on Tuesday, June 20, 2017. Management is scheduled to present at 3:30 p.m. Eastern Time. A live audio webcast of the presentation may be accessed by visiting the Investors page of AtriCure’s corporate website at ir.atricure.com. A replay of the presentation will be available for 90 days following the pres...

MASON, Ohio--(BUSINESS WIRE)--Apr. 7, 2017-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that it will release its first quarter 2017 financial results on Thursday, May 4, 2017. AtriCure will host a conference call at 4:30 p.m. Eastern Time on Thursday, May 4, 2017 to discuss its first quarter 2017 financial results. The call may be accessed through an operator by calling (844) 884-9951 for domestic callers and (661) 378-9661 for international callers using conference ID number 45359788. A live audi...

MASON, Ohio--(BUSINESS WIRE)--Mar. 14, 2017-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage management, today announced that it has named Dr. David B. DeLurgio as the national principal investigator (PI) for the CONVERGE IDE clinical trial. Dr. DeLurgio is a cardiac electrophysiologist at Emory Healthcare in Atlanta, GA. He is Director of Electrophysiology at the Emory Heart and Vascular Center at Emory St. Joseph’s Hospital, a role he has served in since 2014. Dr. DeLurgio earned his medical degree from the University of Californi...

MASON, Ohio--(BUSINESS WIRE)--Mar. 6, 2017-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage management, today announced it has hired Vinayak (Vini) Doraiswamy, PhD as its Senior Vice President of Clinical, Regulatory, and Scientific Affairs. Most recently, Dr. Doraiswamy served as Vice President of Global Clinical Operations at St. Jude Medical. In his role he oversaw clinical operations for over 100 clinical trials across the world, and managed a team of over 300 people. During his time at St. Jude Medical, he led the integration o...

MASON, Ohio--(BUSINESS WIRE)--Feb. 3, 2017-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that it will release its fourth quarter and full year 2016 financial results on Tuesday, February 28, 2017. AtriCure will host a conference call at 4:30 p.m. Eastern Time on Tuesday, February 28, 2017 to discuss its fourth quarter and full year 2016 financial results. The call may be accessed through an operator by calling (844) 884-9951 for domestic callers and (661) 378-9661 for international callers using confer...

MASON, Ohio--(BUSINESS WIRE)--Jan. 24, 2017-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that it will present at the Leerink Partners Global Healthcare Conference at the Palace Hotel in New York City on Thursday, February 16, 2017. Management is scheduled to present at 9:30 a.m. Eastern Time. A live audio webcast of the presentation may be accessed by visiting the Investors page of AtriCure’s corporate website at ir.atricure.com. A replay of the presentation will be available for 90 days following the pre...

MASON, Ohio--(BUSINESS WIRE)--Dec. 15, 2016-- AtriCure, Inc. (Nasdaq:ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that it will present at the 35th Annual JP Morgan Healthcare Conference at the Westin St. Francis Hotel in San Francisco on Thursday, January 12, 2017. Management is scheduled to present at 9:30 a.m. Pacific Time. A live audio webcast of the presentation may be accessed by visiting the Investors page of AtriCure’s corporate website at www.atricure.com. A replay of the presentation will be available for 90 days following the ...

MASON, Ohio--(BUSINESS WIRE)--Nov. 7, 2016-- AtriCure, Inc. (Nasdaq:ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that it will present at the Piper Jaffray 28th Annual Healthcare Conference at the Lotte New York Palace Hotel in New York City on Wednesday, November 30, 2016. Management is scheduled to present at 11:30 a.m. Eastern Time. A live audio webcast of the presentation may be accessed by visiting the Investors page of AtriCure’s corporate website at www.atricure.com. A replay of the presentation will be available for 90 days...

Revenue of $38.3 million – up 22.0% U.S. sales of $30.6 million – up 24.0% International sales of $7.8 million – up 14.9% MASON, Ohio--(BUSINESS WIRE)--Oct. 27, 2016-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced third quarter 2016 financial results. “We are pleased to report solid third quarter results led by sales in the U.S. and driven by all areas of our business,” said Mike Carrel, President and Chief Executive Officer of AtriCure. “Our focus on improvin...

MASON, Ohio--(BUSINESS WIRE)--Oct. 4, 2016-- AtriCure, Inc. (Nasdaq:ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage management, will release its financial results for the third quarter of 2016 on Thursday, October 27, 2016. AtriCure will host a conference call at 4:30 p.m. Eastern Time on Thursday, October 27, 2016 to discuss its third quarter 2016 financial results. The call may be accessed through an operator by calling (844) 884-9951 for domestic callers and (661) 378-9661 for international callers using conference ID number 91346855. A live webcast of the confer...

Revenue of $39.7 million – up 21.8% as reported, 21.5% constant currency U.S. sales of $30.9 million – up 19.9% International sales of $8.8 million – up 28.7% as reported, 27.4% constant currency MASON, Ohio--(BUSINESS WIRE)--Aug. 4, 2016-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced second quarter 2016 financial results. “We are pleased to report second quarter results which reflect many accomplishments – we launched two new products, made progress with...

MASON, Ohio--(BUSINESS WIRE)--Jul. 11, 2016-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage management, will release its financial results for the second quarter of 2016 on Thursday, August 4, 2016. AtriCure will host a conference call at 4:30 p.m. Eastern Time on Thursday, August 4, 2016 to discuss its second quarter 2016 financial results. A live webcast of the conference call will be available online on the Investor page of AtriCure’s corporate website at www.atricure.com. You may also access this call through an operator by calling (855) ...

MASON, Ohio--(BUSINESS WIRE)--May 2, 2016-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage management, today announced that it will present at the UBS Global Healthcare Conference at the Grand Hyatt in New York on Monday, May 23, 2016. Management is scheduled to present at 11:00 a.m. Eastern Time. A live audio webcast of the presentation may be accessed by visiting the Investors page of AtriCure’s corporate website at www.atricure.com. A replay of the presentation will be available for 90 days following the presentation. About AtriCure, Inc....

MASON, Ohio--(BUSINESS WIRE)--Apr. 28, 2016-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage management, today announced that it has entered into an amended and restated term loan and revolving line of credit agreement with Silicon Valley Bank, providing access to a new $25 million five-year term loan, as well as renewing a $15 million revolving line of credit. "We are pleased to have Silicon Valley Bank as a partner," said Andy Wade, Senior Vice President and Chief Financial Officer of AtriCure. "This loan facility strengthens our balance sheet an...

Clearance brings an even more flexible probe to the U.S. market for use in a variety of surgical interventions to treat cardiac arrhythmias; product was launched in Europe in October 2015 MASON, Ohio--(BUSINESS WIRE)--Apr. 12, 2016-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage management, today announced that it has received 510(k) clearance for the cryoFORM cryoablation probe, which offers increased probe flexibility to adapt to a variety of surgical ablation procedures. The probe was previously launched in October 2015 in the Europea...

2015 revenue of $129.8 million – up 20.8% as reported, 23.8% constant currency 2015 U.S. sales of $102.2 million – up 27.4% Fourth quarter 2015 revenue of $35.9 million – up 21.9% as reported, 24.0% constant currency MASON, Ohio--(BUSINESS WIRE)--Feb. 23, 2016-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage management, today announced fourth quarter and full year 2015 financial results. “We are pleased to report strong 2015 results, positioning us well in 2016 as we continue to execute on ...

WEST CHESTER, Ohio--(BUSINESS WIRE)--Feb. 1, 2016-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage management, will release its financial results for the fourth quarter and full year 2015 on Tuesday, February 23, 2016. AtriCure will host a conference call at 4:30 p.m. Eastern Time on Tuesday, February 23, 2016 to discuss its fourth quarter and full year 2015 financial results. A live webcast of the conference call will be available online on the Investor page of AtriCure’s corporate website at www.atricure.com. You may also access this call through...

MASON, Ohio--(BUSINESS WIRE)--Jan. 11, 2016-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage management, today announced preliminary financial results for fourth quarter and full year 2015 and updated 2016 financial guidance. Preliminary and unaudited revenue for fourth quarter 2015 is expected to be approximately $35.9 million, reflecting growth of approximately 21.9% over the fourth quarter of 2014. Based on this preliminary estimate, revenue from U.S. customers is expected to be $28.9 million, reflecting growth of 30.7%, and revenue from interna...

WEST CHESTER, Ohio--(BUSINESS WIRE)--Nov. 23, 2015-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage management, today announced that it will present at the Piper Jaffray Healthcare Conference at the Palace Hotel in New York City on Tuesday, December 1, 2015. Management is scheduled to present at 10:30 a.m. Eastern Time. A live audio webcast of the presentation may be accessed by visiting the Investors page of AtriCure’s corporate website at www.atricure.com. A replay of the presentation will be available for 90 days following the presentation. ...

Revenue of $31.4 million – up 17.8% as reported, 20.6% constant currency U.S. sales of $24.7 million – up 23.0% International sales of $6.7 million – up 2.1% as reported, 13.2% constant currency WEST CHESTER, Ohio--(BUSINESS WIRE)--Oct. 27, 2015-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage management, today announced third quarter 2015 financial results. “We are pleased with our performance in the third quarter and excited about our prospects for sustained growth,” said Mike Carrel, Pre...

WEST CHESTER, Ohio--(BUSINESS WIRE)--Oct. 8, 2015-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage management, will release its financial results for the third quarter of 2015 on Tuesday, October 27, 2015. AtriCure will host a conference call at 4:30 p.m. Eastern Time on Tuesday, October 27, 2015 to discuss its third quarter 2015 financial results. A live webcast of the conference call will be available online on the Investor page of AtriCure’s corporate website at www.atricure.com. You may also access this call through an operator by calling (855)...

Offering expands on the company’s cryoablation suite of products by introducing an even more flexible probe for use in a variety of surgical interventions to treat cardiac arrhythmias WEST CHESTER, Ohio--(BUSINESS WIRE)--Sep. 30, 2015-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage management, today announced the launch of the cryoFORM™ cryoablation probe, which offers increased probe flexibility to adapt to a variety of surgical ablation procedures. This offering adds to the cryoICE™ family of ablation products which are used in the cry...

Revenue of $32.6 million – up 22.9% as reported, 26.5% constant currency U.S. sales of $25.7 million – up 29.3% International sales of $6.8 million – up 3.5% as reported, 17.9% constant currency WEST CHESTER, Ohio--(BUSINESS WIRE)--Jul. 28, 2015-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in technologies for the surgical treatment of atrial fibrillation and left atrial appendage management, today announced second quarter 2015 financial results. “We are pleased by our results this quarter which reflect continued stability in our business and the solid foun...

WEST CHESTER, Ohio--(BUSINESS WIRE)--Jul. 7, 2015-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in technologies for the surgical treatment of atrial fibrillation and left atrial appendage management, will release its financial results for the second quarter of 2015 on Tuesday, July 28, 2015. AtriCure will host a conference call at 4:30 p.m. Eastern Time on Tuesday, July 28, 2015 to discuss its second quarter 2015 financial results. A live webcast of the conference call will be available online on the Investor page of AtriCure’s corporate website at www.atricure.com. You may also access this call through an operator...

Revenue of $29.9 million – up 20.3% as reported, 24% constant currency U.S. sales of $22.9 million – up 26.3% International sales of $7.0 million – up 3.9% as reported, 17.6% constant currency WEST CHESTER, Ohio--(BUSINESS WIRE)--Apr. 29, 2015-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in technologies for the surgical treatment of atrial fibrillation and left atrial appendage management, today announced first quarter 2015 financial results. “We had a strong start to the year and remain well positioned to help treat patients suffering from atrial fibrillation thro...

WEST CHESTER, Ohio--(BUSINESS WIRE)--Apr. 8, 2015-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in technologies for the surgical treatment of atrial fibrillation and left atrial appendage management, will release its financial results for the first quarter of 2015 on Wednesday, April 29, 2015. AtriCure will host a conference call at 4:30 p.m. Eastern Time on Wednesday, April 29, 2015 to discuss its first quarter 2015 financial results. A live webcast of the conference call will be available online on the Investor page of AtriCure’s corporate website at www.atricure.com. You may also access this call through an oper...

WEST CHESTER, Ohio--(BUSINESS WIRE)--Mar. 25, 2015-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation and Left Atrial Appendage Management, today announced that it will present at the Needham Healthcare Conference at the Westin Grand Central Hotel in New York on Tuesday, April 14, 2015. Management is scheduled to present at 8:00 a.m. Eastern Time. A live audio webcast of the presentation may be accessed by visiting the Investors page of AtriCure’s corporate website at www.atricure.com. A replay of the presentation will be available for 90 days following the presentation. ...

WEST CHESTER, Ohio--(BUSINESS WIRE)--Mar. 5, 2015-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation and Left Atrial Appendage Management, will host an analyst and institutional investor meeting on Tuesday, March 24, 2015, in New York City from 8:00 a.m. to approximately 10:00 a.m. Eastern Time. The meeting will include remarks from the AtriCure management team highlighting the company’s strategy for executing on its growth initiatives as well as guest speakers to provide clinical perspective. Guest speakers: James L. Cox, M.D., cardiothoracic surge...

The collaborative study between cardiac surgeons and electrophysiologists to deliver innovative solutions and new treatment options for Atrial Fibrillation WEST CHESTER, Ohio--(BUSINESS WIRE)--Feb. 24, 2015-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in technologies for the surgical treatment of atrial fibrillation (Afib) and left atrial appendage management, today announced the first two patients have been enrolled and treated at PinnacleHealth CardioVascular Institute in Harrisburg, Pennsylvania, in the Dual Epicardial and Endocardial Procedure (DEEP) clinical study. The pivotal study is the first of ...

WEST CHESTER, Ohio--(BUSINESS WIRE)--Feb. 2, 2015-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation and Left Atrial Appendage Management, will release its financial results for the fourth quarter and full year 2014 on Monday, February 23, 2015. AtriCure will host a conference call at 4:30 p.m. Eastern Time on Monday, February 23, 2015 to discuss its fourth quarter and full year 2014 financial results. A live webcast of the conference call will be available online from the investor relations page of AtriCure’s corporate website at www.atricure.com. You may also acces...

WEST CHESTER, Ohio--(BUSINESS WIRE)--Jan. 14, 2015-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation and Left Atrial Appendage Management, today announced that Douglas Seith will assume the role of Chief Operating Officer. Mr. Seith will now be responsible for all global commercial organizations as well as education and clinical science programs. The company also announced that Andy Wade has been promoted to Senior Vice President and Chief Financial Officer. Mr. Seith has over 25 years of cardiology and general surgery sales and sales leadership experience and has served a...

AtriCure will investigate a minimally invasive approach to treat patients with persistent or long-standing persistent atrial fibrillation who have failed antiarrhythmic drug therapy WEST CHESTER, Ohio--(BUSINESS WIRE)--Nov. 3, 2014-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage management (LAAM), today announced it has received approval for an Investigational Device Exemption from the U.S. Food and Drug Administration (FDA) to begin enrollment in the Dual Epicardial and Endocardial Procedure (DEEP) clinical trial. The DEEP tria...

Revenue of $26.7 million – up 32.4% U.S. sales of $20.1 million – up 26.7% International sales of $6.6 million – up 53.4%; 53.9% constant currency WEST CHESTER, Ohio--(BUSINESS WIRE)--Oct. 30, 2014-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation (“Afib”) and Left Atrial Appendage Management (“LAAM”), today announced financial results for the third quarter of 2014. “We had a strong third quarter with momentum across all of our product lines in both the U.S. and internationally. We continue to see increasing ph...

WEST CHESTER, Ohio, Oct. 3, 2014 (GLOBE NEWSWIRE) -- AtriCure, Inc. (Nasdaq:ATRC), a leading innovator in surgical treatments for atrial fibrillation and left atrial appendage management, will release its financial results for the third quarter of 2014 on Thursday, October 30, 2014. AtriCure will host a conference call at 4:30 p.m. Eastern Time on Thursday, October 30, 2014 to discuss its third quarter 2014 financial results. A live webcast of the conference call will be available online from the investor relations page of AtriCure's corporate website at www.AtriCure.com. You may also access this call through an operator by calling (800) 510-0219 for domestic callers and (617) 614-3451 f...

WEST CHESTER, Ohio--(BUSINESS WIRE)--Jul. 29, 2014-- AtriCure, Inc. (Nasdaq: ATRC), a leading atrial fibrillation medical device provider, today announced that it will present at the Canaccord Genuity 34th Annual Growth Conference at the Intercontinental Hotel in Boston on Wednesday, August 13, 2014. Management is scheduled to present at 8:30 a.m. Eastern Time. A live audio webcast and replay of the presentation will be available for 30 days following the presentation at http://wsw.com/webcast/canaccord14/atrc. AtriCure management is also scheduled to participate in the Barrington Research 7th Annual Fall Investment Confe...

AtriClip is the most widely used device indicated for left atrial appendage management WEST CHESTER, Ohio--(BUSINESS WIRE)--Jul. 16, 2014-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation (Afib), today announced that it has sold more than 34,000 AtriClip® Left Atrial Appendage Exclusion System devices worldwide, quickly becoming the top selling device used for eliminating the left atrial appendage (LAA). The LAA is a muscular pouch attached to the heart’s left atrium. In patients with Afib and other cardiac arrhythmias, blood can pool and form clot...

WEST CHESTER, Ohio--(BUSINESS WIRE)--May 28, 2014-- AtriCure, Inc. (Nasdaq: ATRC), a leading atrial fibrillation medical device provider, today announced that it will present at the 9th Annual JMP Securities Healthcare Conference at The Westin New York Grand Central on Tuesday, June 24, 2014. Management is scheduled to present at 1:30 p.m. Eastern Time. A live audio webcast and replay of the presentation will be available for 90 days following the presentation at http://wsw.com/webcast/jmp24/ATRC. About AtriCure, Inc. AtriCure, Inc. is a medical device company providing innovative atrial fibrillation (Afib)...

Revenue of $24.8 million – up 27.9% U.S. sales of $18.1 million – up 23.9% International sales of $6.7 million – up 39.9%; 36.4% constant currency WEST CHESTER, Ohio--(BUSINESS WIRE)--Apr. 24, 2014-- AtriCure, Inc. (Nasdaq: ATRC), a leading atrial fibrillation (“Afib”) medical device provider, today announced financial results for the first quarter of 2014. “We are off to a strong start in 2014, as our commitment to training and education, clinical trial support and innovation continue to pay dividends. We are seeing increasing physician interest in treating patients ...

WEST CHESTER, Ohio--(BUSINESS WIRE)--Feb. 28, 2014-- AtriCure, Inc. (Nasdaq: ATRC), a leading atrial fibrillation medical device provider, today announced that it will present at the Cowen and Company 34th Annual Health Care Conference at the Boston Marriott Copley Place on Wednesday, March 5, 2014. Management is scheduled to present at 9:20 a.m. Eastern Time. A live audio webcast and replay of the presentation will be available for 30 days following the presentation at www.atricure.com. About AtriCure, Inc. AtriCure, Inc. is a medical device company providing innovative atrial fibrillation (Afib) s...

WEST CHESTER, Ohio--(BUSINESS WIRE)--Feb. 13, 2014-- AtriCure, Inc. (Nasdaq: ATRC), a leading atrial fibrillation medical device provider, today announced the pricing of its previously announced underwritten public offering of 4,250,000 shares of its common stock at a public offering price of $19.25 per share. AtriCure is offering 3,023,025 shares and selling stockholders are offering 1,226,975 shares of common stock. In connection with the offering, AtriCure has also granted the underwriter a 30-day option to purchase up to an additional 637,500 shares of common stock to cover over-allotments, if any. Net proceeds from t...

WEST CHESTER, Ohio--(BUSINESS WIRE)--Feb. 4, 2014-- AtriCure, Inc. (Nasdaq: ATRC), a leading atrial fibrillation medical device provider, will release its financial results for the fourth quarter and full year 2013 on Thursday, February 27, 2014. AtriCure will host a conference call at 4:30 p.m. Eastern Time on Thursday, February 27, 2014 to discuss its fourth quarter and full year 2013 financial results. A live webcast of the conference call will be available online from the investor relations page of AtriCure’s corporate website at www.atricure.com. Pre-registration is available and recommended for this call at ...

WEST CHESTER, Ohio--(BUSINESS WIRE)--Jan. 9, 2014-- AtriCure, Inc. (Nasdaq: ATRC), a leading atrial fibrillation medical device provider, today announced preliminary financial results for fourth quarter and full year 2013 and issued 2014 financial guidance. Preliminary revenue for the fourth quarter of 2013 is expected to be approximately $21.9 million, reflecting growth of approximately 19% over the fourth quarter of 2012. Based on this preliminary estimate, revenue from U.S. customers is expected to be $16.4 million, reflecting growth of 20%, and revenue from international customers is expected to be $5.5 million, refle...

WEST CHESTER, Ohio--(BUSINESS WIRE)--Dec. 19, 2013-- AtriCure, Inc. (Nasdaq: ATRC), a leading Atrial Fibrillation (Afib) medical device provider, and Endoscopic Technologies, Inc. d/b/a Estech (“Estech”), today announced that they have entered into a definitive merger agreement under which AtriCure has agreed to acquire Estech for a cash-free, debt-free up-front payment of approximately 2.1 million shares or $34 million of AtriCure common stock and up to $26 million in additional consideration based on the achievement of certain revenue-based milestones. The transaction is subject to customary closing conditions and is expected t...

WEST CHESTER, Ohio--(BUSINESS WIRE)--Oct. 31, 2013-- AtriCure, Inc. (Nasdaq: ATRC), a leading Atrial Fibrillation medical device provider, today announced that it will be participating in the following upcoming investor conferences: The 2013 Canaccord Genuity Medical Technology & Diagnostics Forum at the Westin Grand Central Hotel in New York on November 14, 2013. The Piper Jaffray 2013 Annual Health Care Conference at the New York Palace Hotel on December 4, 2013. About AtriCure, Inc. AtriCure, Inc. is a leading atrial fibrillation solutions partner, providin...

WEST CHESTER, Ohio--(BUSINESS WIRE)--Oct. 7, 2013-- AtriCure, Inc. (Nasdaq: ATRC), a leading atrial fibrillation solutions partner providing innovative products, professional education and support for clinical science to reduce the economic and social burden of atrial fibrillation, will release its financial results for the third quarter of 2013 on Tuesday, October 29, 2013. AtriCure will host a conference call at 4:30 p.m. Eastern Time on Tuesday, October 29, 2013 to discuss its third quarter 2013 financial results. A live webcast of the conference call will be available online from the investor relations page of AtriCur...